Literature DB >> 6126342

Metabolism of aminoglutethimide in the rat.

H Egger, F Bartlett, W Itterly, R Rodebaugh, C Shimanskas.   

Abstract

The metabolism of aminoglutethimide was studied in the rat by use of the 14C-labeled compound. Following oral doses of 5 and 50 mg/kg, the drug was almost completely eliminated within 48 hr into urine and feces, mostly in the form of metabolites. In bile duct-cannulated rats, biliary excretion of radioactivity amounted to about 52% within 24 hr of an orally administered 50 mg/kg dose, with the remainder of the dose being eliminated into urine. The major urinary metabolites resulted from acetylation of the aniline moiety, hydroxylation of the glutarimide ring at positions 3 and 4, and oxidative elimination of the ethyl sidechain. The polar metabolites are accounted for by aromatic hydroxylation with subsequent sulfate conjugation and by a glutarimide ring-opened compound. In addition, a gamma-butyrolactone derivative was also identified.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126342

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

3.  Single-dose and steady-state pharmacokinetics of aminoglutethimide.

Authors:  P E Lønning; J S Schanche; S Kvinnsland; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

4.  Tissue distribution and elimination of 14C-aminoglutethimide in the mouse.

Authors:  P D Dalrymple; P J Nicholls
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.